Mitsubishi Tanabe Pharma America Presents New Results of RADICAVA ORS® (edaravone) from a Phase 3b Efficacy and Safety Extension Study and a Clinical Analysis of Multiple Studies at NEALS 2024
Phase 3b extension study reinforces current FDA-approved on/off regimen of RADICAVA ORS


